Etoricoxib Provides Analgesic Efficacy to Patients After Knee or Hip Replacement Surgery: A Randomized, Double-Blind, Placebo-Controlled Study
| Autor: | Maurice Jove, Alise S. Reicin, Michael H. Bourne, Kerstin Malmstrom, Paul Kotey, Steven M. Rhondeau, G. Lynn Rasmussen, Michelle L. Aversano, Jennifer Ang |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Analgesic effect medicine.medical_specialty Pyridines Arthroplasty Replacement Hip Analgesic Placebo-controlled study Hip replacement (animal) Double blind Etoricoxib Double-Blind Method medicine Humans Severe pain Cyclooxygenase Inhibitors In patient Sulfones Arthroplasty Replacement Knee Aged Pain Postoperative business.industry Middle Aged Surgery Anesthesiology and Pain Medicine Anesthesia Female business medicine.drug |
| Zdroj: | Anesthesia & Analgesia. 101:1104-1111 |
| ISSN: | 0003-2999 |
| DOI: | 10.1213/01.ane.0000169294.41210.9e |
| Popis: | In this randomized, double-blind, placebo-controlled, multicenter study we assessed the analgesic effect of etoricoxib (a new cyclooxygenase-2 inhibitor) in patients having had knee or hip replacement surgery. A total of 228 patients with moderate or severe pain were randomly allocated within 72 h after surgery to receive etoricoxib 120 mg, controlled-release naproxen sodium 1100 mg, or placebo (1:1:1) on day 1 followed by etoricoxib and placebo (1:2) on days 2 to 7. Patients reported pain scores, rescue (opioid-combination) medication use, and the response to study drug. On day 1, etoricoxib provided an analgesic effect superior to placebo and similar to controlled-release naproxen sodium as demonstrated by the total pain relief score over 8 h, the primary end-point; least-squares mean scores were 11.0, 11.5, and 5.6, respectively (P0.001 versus placebo). Similarly, a larger percentage of patients receiving etoricoxib and naproxen sodium than those receiving placebo reported good to excellent responses to study drug: 53%, 60%, and 26% respectively. On days 2-7, etoricoxib demonstrated a significant reduction of rescue medication use, 35% (P0.001 versus placebo). The clinical relevance of the decrease was confirmed by Patient's Global Evaluation (P0.05 versus placebo). Patients receiving etoricoxib also experienced significantly less "worst" and "average" pain than did those on placebo. Etoricoxib was generally well tolerated in this study; the incidence of adverse experiences was infrequent and similar across treatment groups. In summary, etoricoxib provided analgesia that was similar to controlled-release naproxen sodium on day 1 and superior to placebo with reduced supplemental opioid use over 7 days.In a postsurgery setting (knee and hip replacements), etoricoxib 120 mg provided analgesia superior to placebo and similar to controlled-release naproxen sodium 1100 mg. Patients receiving etoricoxib suffered less pain and took less opioid rescue medication compared with patients on placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|